• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific’s Acurate Neo2 valve performs well in studies

Boston Scientific’s Acurate Neo2 valve performs well in studies

May 20, 2022 By Sean Whooley

Boston Scientific Acurate Neo2 heart valve
Acurate Neo2 [Image from Boston Scientific]
Boston Scientific (NYSE:BSX) announced positive outcomes from studies of its Acurate Neo2 aortic valve system.

Initial outcomes from the Neo-Align study of 170 patients who underwent transcatheter aortic valve implantation (TAVI) with Acurate Neo2 using a novel implant technique to attempt commissural alignment of the prosthetic and native valves demonstrated that commissural alignment can be achieved safely, effectively and quickly.

Data showed that 97% of patients had no significant misalignment (80% none, 17% mild, 1.2% moderate and 1.8% severe), and the average alignment time of 92 seconds had a minimal impact on procedure duration, according to Boston Scientific. Post-procedure and 30-day safety events were consistent with expected TAVI complication rates, while small manipulations of the delivery system in the ascending aorta did not adversely impact safety outcomes.

The company also reported new findings from the ITAL-neo registry, a two-arm, retrospective registry of 900 patients from 13 Italian centers.

Data from the registry showed that Acurate Neo2 produced superior performance compared to the previous generation (Acurate Neo), reinforcing the enhanced ability of the valve to minimize paravalvular leak (PVL) with its sealing technology. The study met its primary endpoint with a three-fold reduction in more-than-mild paravalvular aortic regurgitation with Acurate Neo2 (11.5% for the first generation valve, 3.5% for Acurate Neo2).

There was also a numerically higher in-hospital technical device success rate and improved success and safety outcomes at 90 days — the secondary endpoints for the registry — for Acurate Neo 2.

Boston Scientific also presented investigator-driven studies and e-posters with new data on coronary access and post-implant PVL with both valves, all at the EuroPCR 2022 conference.

A study evaluated coronary access after valve-in-SAVR (surgical aortic valve replacement) TAVI, using a simulation of coronary cannulation (catheterization) procedures in patient-specific 3D-printed models derived from post-procedural CT imaging. The study demonstrated that, despite the supra-annular design of the Acurate Neo valve, coronary access for diagnostic angiography and PCI was highly feasible.

Boston Scientific’s Predict PVL study, which aimed to evaluate PVL after implantation using postprocedural transthoracic (TTE) and transesophageal (TEE) echocardiography and computed tomography, observed a 48% reduction (statistically significant) in the cumulative effective regurgitation orifice area (EROA) with Acurate Neo2 compared to Acurate Neo.

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Featured, Implants, News Well, Replacement Heart Valves, Structural Heart Tagged With: Boston Scientific, TAVI, tavr

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy